术中升压药使用不增加乳房切除术后微血管乳房再造并发症:单中心1729例DIEP皮瓣经验
该回顾性队列研究纳入2010年1月至2020年5月单中心1102例女性1729例DIEP皮瓣乳房再造,比较术中接受与未接受升压药患者的微血管结局。878例(79.7%)术中接受苯肾上腺素、麻黄碱或两者联用。两组总体并发症、术中微血管事件、因微血管并发症再次手术及部分或全部皮瓣丢失均无显著差异;升压药组术中输液量显著更低。多因素logistic回归显示总体并发症与输液过多显著相关(OR 2.03,99%CI 0.98-5.18,p=0.03),而与升压药使用无关(OR 0.79,99%CI 0.64-3.16,p=0.7)。
要点
- 术中升压药未显著增加DIEP皮瓣总体并发症、微血管事件或皮瓣丢失。
- 升压药类型、剂量及给药时机均不影响结局。
- 升压药组术中输液量显著更低;输液过多与总体并发症显著相关。
核心结论
- 本研究表明升压药对DIEP乳房再造术后临床结局无不良影响。
- 不使用升压药导致静脉输液过多并增加术后并发症。
研究设计与样本
- 回顾性病历审查,纳入2010年1月至2020年5月单中心接受DIEP乳房再造的患者。
- 共1102例女性、1729例DIEP皮瓣;比较术中接受与未接受升压药患者的术中及术后微血管结局。
主要发现
- 878例(79.7%)术中接受苯肾上腺素、麻黄碱或两者联用。
- 两组总体并发症、术中微血管事件、因微血管并发症再次手术及部分或全部皮瓣丢失均无显著差异。
- 结局不受升压药类型、剂量或给药时机影响。
- 升压药组术中输液量显著低于未使用升压药组。
- 多因素logistic回归显示总体并发症与输液过多显著相关(OR 2.03,99%CI 0.98-5.18,p=0.03),与升压药使用无关(OR 0.79,99%CI 0.64-3.16,p=0.7)。
临床怎么用
- 作者认为升压药对DIEP乳房再造术后临床结局无不良影响,不使用升压药会导致静脉输液过多并增加术后并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vasopressors are traditionally avoided in microsurgery due to concerns about their effect on free flap survival. We examine the impact of intraoperative vasopressors on microsurgical outcomes in a large series of DIEP flap breast reconstructions. METHODS: A retrospective chart review was performed of patients who underwent DIEP breast reconstruction between January 2010 and May 2020. Intraoperative and postoperative microsurgical outcomes were compared in patients who received vasopressors and those who did not. RESULTS: The study included 1102 women who underwent 1729 DIEP. 878 patients (79.7%) received intraoperative phenylephrine, ephedrine, or a combination of both. There was no significant difference in overall complications, intraoperative microvascular events, takebacks for microvascular complications, or partial or total flap loss between groups. Outcomes were not affected by vasopressor type, dose, or timing of administration. The vasopressor group received significantly lower intraoperative fluid volumes. Multivariate logistic regression found a significant association between overall complications and excessive fluids (OR 2.03, 99% CI 0.98-5.18, p = 0.03) but not vasopressor use (OR 0.79, 99% CI 0.64-3.16, p = 0.7) CONCLUSION: This study demonstrates that vasopressors do not adversely affect clinical outcomes after DIEP breast reconstruction. Withholding vasopressors results in excessive intravenous fluid administration and increased postoperative complications.
引用
- Zhu A, Perrotta A, Choi V, et al. Intraoperative vasopressor use does not increase complications in microvascular post-mastectomy breast reconstruction: Experience in 1729 DIEP flaps at a single center. J Plast Reconstr Aesthet Surg. 2023. PMID: 37315455. doi:10.1016/j.bjps.2023.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。